News for Portage Biotech Inc. (PRTG)

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ('Portage” or the 'Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended March 31, 2025.

Massachusetts-based Vor Biopharma Inc. (VOR), a clinical-stage cell and genome engineering company is up over 109 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

On June 5, Portage Biotech (PRTG) entered into a Subscription Agreement with Compedica Holdings. As part of this agreement, Portage issued 625,000 of its ordina

Portage Biotech (PRTG) enters a $5 million stock-for-stock deal with Compedica Holdings. Compedica to hold 27.4% of Portage's shares post-transaction.

**media[649113]**

Key Takeaways: Insider activity shows a net purchase worth $900,000, indicating confidence in Portage Biotech's future. Analyst views suggest an average

Portage Biotech, under the ticker PRTG, has unveiled promising preclinical findings for PORT-7, a selective inhibitor of the adenosine A2B receptor. The researc

DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ( PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical

**media[607297]**

Portage Biotech has resumed patient enrollment in its critical PORT-6 dose escalation trial, showing recovery from past financial setbacks. Analysts pre

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 500 points on Friday. The Dow traded down 1.21% to 41,788.66 while ...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Friday. Following the market opening Friday, the Dow traded down ...

Portage Biotech Inc (PRTG), a clinical stage immune-oncology company is up over 155 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Shares of Portage Biotech Inc. (PRTG) were up over 100% in after-hours trading on Thursday, following promising preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor, given as a single agent or in combination with anti-PD-1 antibody in a murine model of mesothelioma.

Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti

**media[578930]**

Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients DOVER, Del., March 12, 2025

DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (”œPortage” or the ”œCompany”) ( PRTG), a clinical-stage immuno-oncology company wi